Dabigatran for catastrophic antiphospholipid syndrome
Por:
Sarrate, E, Olive, A, Morales-Indiano, C, Santos-Gomez, M, Orna, E, Monreal, M and Sorigue, M
Publicada:
1 oct 2019
Resumen:
Vitamin K antagonists (VKA) remain the treatment of choice for catastrophic antiphosphilipid syndrome (CAPS). However, when VKAs do not work for a specific patient, direct oral anticoagulants (DOAC) may be a valid therapeutic alternative. We present a patient with a psychiatric disorder and CAPS who was noncompliant to VKA and low-molecular-weight heparin. He was started on dabigatran and has remained thrombosis-free for 8 years. Due to CAPS he has developed progressive renal failure but dabigatran levels were within the expected range. In conclusion, this case report provides anecdotic evidence that dabigatran may be of use in patients with high-risk APS in whom VKA are not an option.
Filiaciones:
Sarrate, E:
Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Hematol Lab,ICO Badalona, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Rheumatol Serv, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Core Hematol Dept, Clin Lab ICS Metropolitana Nord, Barcelona, Spain
Santos-Gomez, M:
Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Hematol Lab,ICO Badalona, Barcelona, Spain
:
Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Hematol Lab,ICO Badalona, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Dept Internal Med, Barcelona, Spain
:
Univ Autonoma Barcelona, Inst Recerca Josep Carreras, Hosp Germans Trias & Pujol, Hematol Lab,ICO Badalona, Barcelona, Spain
|